CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Adherehealth and Levrx Technology Establish a Strategic Partnership to Improve Medication Optimization

Adherehealth and Levrx Technology...

Clinical Researchs Most Recent Developments

Clinical Researchs Most Recent...

Giuliano to Lead Finance-Related Leadership Functions as New CFO at Aeterna

Giuliano to Lead Finance-Related...

Top Ways Netsuite Transforms Life Science Industry for Good

Top Ways Netsuite Transforms Life...

Rain Therapeutics and Roche to Jointly Conduct Immunotherapy Trial Solid Tumor Treatment

Rain Therapeutics and Roche to...

China biopharma sector focuses on innovation.

China biopharma sector focuses on...

4 Common Challenges in Clinical Trials - How Are You Addressing Them?

4 Common Challenges in Clinical...

What are the Key Pain Points in Managing Clinical Trials?

What are the Key Pain Points in...

Adherehealth and Levrx Technology Establish a Strategic Partnership to Improve Medication Optimization

Adherehealth and Levrx Technology...

Clinical Researchs Most Recent Developments

Clinical Researchs Most Recent...

Giuliano to Lead Finance-Related Leadership Functions as New CFO at Aeterna

Giuliano to Lead Finance-Related...

Top Ways Netsuite Transforms Life Science Industry for Good

Top Ways Netsuite Transforms Life...

Rain Therapeutics and Roche to Jointly Conduct Immunotherapy Trial Solid Tumor Treatment

Rain Therapeutics and Roche to...

China biopharma sector focuses on innovation.

China biopharma sector focuses on...

4 Common Challenges in Clinical Trials - How Are You Addressing Them?

4 Common Challenges in Clinical...

What are the Key Pain Points in Managing Clinical Trials?

What are the Key Pain Points in...

Aceragen Receives Grant from Cystic Fibrosis Foundation to Advance Novel Therapy

Life Sciences Review Life Sciences Review | Monday, January 24, 2022
Tweet

Cystic Fibrosis Foundation has given Aceragen a $3.5 million grant to develop a novel treatment for CF-related exacerbations.


FREMONT, CA: "We appreciate the generous support of the Cystic Fibrosis Foundation and are looking forward to 2022 as we work closely with the Foundation to initiate clinical development for ACG-701 in CF and multiple other indications," comments John Taylor, Aceragen’s Chief Executive Officer. Aceragen, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for orphan diseases with a high unmet medical need, has a wholly-owned subsidiary, Arrevus. The company has been awarded up to $3.5 million by the Cystic Fibrosis Foundation to assist the clinical development of ACG-701, a proprietary formulation of sodium fusidate, as a treatment for cystic fibrosis-related pulmonary exacerbations. There are no FDA-approved treatments for this indication at the moment.


As a biopharmaceutical firm, Aceragen is dedicated to discovering and developing treatments for the world's most unmet medical needs. Patients with Farber illness and other ceramide-metabolism-related diseases may benefit from ACG-801 (rhAC), an enzyme replacement medication currently being developed by the company. 


 


As part of its Arrevus subsidiary, the company plans to use sodium fusidate, ACG-701, as an oral formulation to treat severe, rare infectious disorders such as cystic fibrosis pulmonary exacerbations. Adding complementary assets to Aceragen's portfolio is a top priority.


Cystic fibrosis (CF) is characterized by persistent respiratory infections that culminate in pulmonary exacerbations. These exacerbations cause an immediate worsening of symptoms, progressive loss of lung function, and decreased survival. ACG-701 contains sodium fusidate, a chemical with a long history of usage outside the United States to treat methicillin-resistant Staphylococcus aureus (MRSA) and associated bacteria that cause exacerbations in the lungs of cystic fibrosis patients.


“The body of data supporting sodium fusidates safety and utility in treating CF pulmonary exacerbations is extensive,” comments Carl Kraus, MD, Aceragens Chief Medical Officer. “Because it has the unusual advantage of its potency increasing many fold under acidic conditions, as well as meaningful anti-inflammatory activity, sodium fusidate is well-suited to treat the frequent, tenacious infections in the inflamed, low-pH environment of the CF lung.”


Weekly Brief

loading
Top 10 Clinical Trial Services Companies - 2022
Top 10 Emerging Clinical Trial Management Companies - 2022
Top 10 Clinical Trial Management System Companies - 2022
Top 10 Clinical Trial Services Companies - 2022
Top 10 Emerging Clinical Trial Management Companies - 2022
Top 10 Clinical Trial Management System Companies - 2022
> <
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue

Read Also

Everything You Need to Know About Medical Lab Equipment and their Applications

Everything You Need to Know About Medical Lab Equipment and their Applications

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural Genome Editing
Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks To Buy In 2022

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/aceragen-receives-grant-from-cystic-fibrosis-foundation-to-advance-novel-therapy-nwid-700.html